Drug Trial Radar · NCT07176650
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
246
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
HLX13Drug
Patients will receive HLX13 (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
YervoyDrug
Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
OPDIVODrug
Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles. Subjects who may continue to benefit from OPDIVO® treatment as assessed by investigators will be subsequently treated with local-sourced OPDIVO® monotherapy every 4 weeks, up to 2 year after randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration-time curve from time 0 to 21 days (AUC0-21d) after the 1st doseTime frame: from time 0 to 21 days after the 1st dose (3 weeks)
- Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss) after the 4th doseTime frame: from time 0 to 78 days after the 4th dose (20 weeks)
Locations
51 sites in 2 countries. Site status is shown where the registry gives one.
Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare
Glendale, California · Recruiting
Los Angeles Cancer Network
Glendale, California · Not yet recruiting
Cancer Specialists of North Florida
Jacksonville, Florida · Not yet recruiting
D&H National Research Centers, LLC
Margate, Florida · Recruiting
Mid Florida Hematology and oncology Center
Orange City, Florida · Recruiting
Florida Clinical Trials Group
Plantation, Florida · Not yet recruiting
Florida Clinical Trials Group
Tamarac, Florida · Not yet recruiting
HCA Research Institute, LLC
Brentwood, Tennessee · Not yet recruiting
Oncology Consultants
Houston, Texas · Recruiting
American Oncology Network Vista Oncology Division/Physician Partner Associate
Olympia, Washington · Recruiting
Northwest Medical Specialties PLLC (NWMS)
Tacoma, Washington · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Peking Union Medical College Hospital
Beijing, China · Recruiting
Peking university international hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China · Recruiting
JiLin Cancer Hospital
Changchun, China · Recruiting
The First Hospital of Jilin University
Changchun, China · Recruiting
People's Hospital of Hunan Province
Changsha, China · Recruiting
Chengdu Fifth People's Hospital
Chengdu, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
Dongguan People's Hospital
Dongguan, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Ganzhou People's Hospital
Ganzhou, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, China · Recruiting
Hainan General Hospital
Haikou, China · Recruiting
Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, China · Recruiting
Jinan Central Hospital
Jinan, China · Recruiting
Affiliated Hospital of Jining Medical University
Jining, China · Recruiting
Linyi Cancer Hospital
Linyi, China · Recruiting
Lishui Central Hospital
Lishui, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Jiangsu Province Hospital
Nanjing, China · Recruiting
The Affiliated Hospital of Nanjing university Medical School
Nanjing, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Shanghai Gobroad Cancer Hospital
Shanghai, China · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.